Carboxypeptidase Z (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Carboxypeptidase Z (CPZ; UniProt Q66K79), produced in HEK293 cells. Suited for C-terminal arginine cleavage assays, Wnt pathway research, and antibody validation against the matched Triple Point Biologics antibody (RP-CarboxypeptidaseZ).
Expression system
HEK293
Cat. #
REC-CarboxypeptidaseZ

In stock

SKU
REC-CarboxypeptidaseZ
$498.00

Target Overview

Carboxypeptidase Z (CPZ; UniProt Q66K79; EC 3.4.17.-) is a secreted zinc-dependent metallocarboxypeptidase encoded by the CPZ gene. The full-length human protein spans 652 amino acids and belongs to the M14 carboxypeptidase family. As a secreted enzyme localised to the extracellular space, CPZ preferentially cleaves C-terminal basic residues — particularly arginine — from peptide substrates, placing it functionally alongside other metallocarboxypeptidases involved in prohormone processing and extracellular proteolytic cascades. This recombinant form is produced in HEK293 mammalian cells, an expression system that supports the glycosylation patterns and disulfide bond formation characteristic of the native secreted protein. Mammalian expression is particularly relevant for CPZ, where proper folding of the cysteine-rich cystatin-like domain is important for zinc coordination and substrate engagement. The HEK293-derived material is therefore well suited for substrate cleavage assays using C-terminally basic peptide reporters, kinetic parameter determination (Km, kcat, Ki), and inhibitor IC50 measurements against small-molecule carboxypeptidase inhibitors. Beyond enzymatic characterisation, CPZ has been studied in the context of Wnt signalling modulation, where it is proposed to act on an as-yet-unidentified extracellular substrate to influence pathway activity. Researchers investigating Wnt-dependent developmental or disease biology use recombinant CPZ to probe these interactions in defined in vitro systems. Researchers requiring an antigenic standard for Western blot or immunohistochemistry validation can pair this recombinant with the matched Triple Point Biologics antibody (RP-CarboxypeptidaseZ), enabling direct confirmation of band identity and specificity in human tissue or cell lysate panels.

Background

Carboxypeptidase Z (CPZ) is a secreted member of the metallocarboxypeptidase family, characterised by a catalytic domain coordinating a zinc ion that is essential for hydrolytic activity. The enzyme exhibits selectivity for substrates bearing C-terminal basic residues, with a documented preference for arginine, a specificity profile shared with carboxypeptidase B-type enzymes but with distinctive structural features conferred by CPZ's cystatin-like N-terminal domain. CPZ was identified as a candidate modulator of the Wnt signalling pathway — one of the central regulatory cascades governing cell fate, proliferation, and tissue patterning across vertebrate development. Although the precise extracellular substrate through which CPZ influences Wnt pathway activity remains to be fully defined, published work has positioned it as a secreted rheostat capable of modifying the activity of extracellular ligands or co-receptors. Researchers studying Wnt-dependent processes use recombinant CPZ in biochemical assays to dissect these extracellular proteolytic events. In addition to its role in developmental signalling, CPZ has been proposed to contribute to prohormone processing, where C-terminal arginine trimming is a common maturation step for neuroendocrine peptides. Studies of peptide hormone biosynthesis have used carboxypeptidase activity assays to establish the contribution of individual family members — including CPZ — to specific processing steps. The cuprizone (CPZ) demyelination mouse model is a widely used experimental system for investigating white matter pathology, myelination, and neuroinflammatory mechanisms relevant to multiple sclerosis research. Recent published studies — including work on remyelination by Kamel AS et al. (2026, Drug Dev Res) — have employed this model to characterise inflammatory mediators, oxidative stress pathways, and candidate therapeutic interventions in a controlled in vivo setting. While the cuprizone abbreviation refers to the copper chelator bis(cyclohexanone)oxaldihydrazone rather than the Carboxypeptidase Z gene, the convergence of the CPZ abbreviation across both contexts underscores the importance of reagent specificity when designing demyelination-related experiments. Recombinant Carboxypeptidase Z protein serves researchers as an enzymatic tool for defining substrate scope, benchmarking inhibitor potency, generating calibration standards for quantitative assays, and validating detection reagents. Its HEK293-derived production provides a glycosylated, properly folded enzyme suitable for biophysical characterisation including surface plasmon resonance and isothermal titration calorimetry binding studies.

Applications

  • Substrate cleavage activity assay using C-terminally basic fluorogenic peptides (e.g., dansyl-Ala-Arg)
  • Inhibitor IC50 determination against small-molecule metallocarboxypeptidase inhibitors
  • Kinetic parameter measurement (Km and kcat) with synthetic arginine-terminated peptide substrates
  • Antibody validation positive control for Western blot, paired with matched Triple Point Biologics antibody RP-CarboxypeptidaseZ
  • Wnt signalling pathway substrate identification by mass spectrometry-based cleavage assay
  • Biophysical characterisation of zinc coordination and enzyme–inhibitor binding by isothermal titration calorimetry or surface plasmon resonance
  • Prohormone processing studies: C-terminal basic residue trimming of neuroendocrine peptide precursors in vitro

References

  1. Kamel AS et al. Unveiling Remyelinating Properties of Roflumilast in CPZ-Induced Neuronal Demyelination in Mice. Drug Dev Res. 2026. doi:10.1002/ddr.70329 PMID: 42207934
  2. Yang J et al. The Myelin-Derived Peptide NSDP1 Suppresses Neuroinflammation and Attenuates Demyelination in Chronic Cuprizone-Fed Mice via Modulation of cGAS-STING Signaling. Neurochem Res. 2026. doi:10.1007/s11064-026-04802-x PMID: 42234285
  3. Nourmohammadi F et al. Co-administration of quercetin and NLRP3 inhibitor attenuates inflammation and oxidative stress in cuprizone-induced demyelination model. Brain Res Bull. 2026. doi:10.1016/j.brainresbull.2026.111967 PMID: 42203077
  4. Fang M et al. Plumbagin ameliorates multiple sclerosis by inducing DDX3X-mediated stress granule assembly in mice. Pharmacol Res. 2026. doi:10.1016/j.phrs.2026.108257 PMID: 42167385
  5. Hao J et al. Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma. Front Pharmacol. 2026. doi:10.3389/fphar.2026.1797067 PMID: 42158948

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); lysosome (some)

Frequently Asked Questions

What is the expected molecular weight of recombinant Carboxypeptidase Z on SDS-PAGE and Western blot?

The full-length human CPZ protein is 652 amino acids, giving a predicted unmodified MW of ~73 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds measurable mass: expect a diffuse band running at approximately 80–90 kDa under reducing SDS-PAGE conditions, consistent with the glycosylation pattern of the native secreted protein. Under non-reducing conditions, intramolecular disulfide bonds in the cystatin-like domain may shift migration slightly. When blotting with RP-CarboxypeptidaseZ, target the 80–90 kDa window for detection.

What processing form of Carboxypeptidase Z does the recombinant represent — pro-form or mature enzyme?

The recombinant material represents the secreted, processed form of CPZ rather than an intracellular zymogen. CPZ contains an N-terminal signal peptide and a prodomain that are cleaved during secretion; HEK293 expression recapitulates this processing, yielding predominantly the mature enzyme competent for zinc coordination and substrate binding. If your experiment requires the latent pro-form, additional precautions or alternative constructs would be needed. For substrate cleavage assays and most binding studies, the HEK293-derived material can be used directly without further activation steps.

What substrates does Carboxypeptidase Z cleave and which are suitable for a fluorogenic activity assay?

CPZ is a zinc-dependent metallocarboxypeptidase (EC 3.4.17.-) that preferentially cleaves C-terminal basic residues, with a strong preference for arginine over lysine. For fluorogenic activity assays, dansyl-Ala-Arg is a well-established small-molecule substrate for the M14 carboxypeptidase family and provides a convenient readout at Ex/Em ~340/520 nm. Hippuryl-Arg (hippuryl-L-arginine) is a chromogenic alternative monitored at 254 nm. Start with substrate concentrations in the 0.1–1 mM range and titrate enzyme from 1–10 nM to establish linear kinetics before running inhibitor or mutant comparisons.

What buffer conditions are recommended for Carboxypeptidase Z activity assays with this recombinant?

The recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 5 mM CaCl₂ — the CaCl₂ is included because CPZ is a metalloproteinase and divalent cations support structural stability. For activity assays, a compatible reaction buffer is 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM CaCl₂. Avoid EDTA or EGTA, which chelate the catalytic zinc and will abolish activity. DTT at concentrations above 1 mM can also interfere with disulfide-dependent folding of the cystatin-like domain; keep reducing agents minimal or absent during assays.

What starting concentration of recombinant Carboxypeptidase Z should I use for a substrate cleavage assay?

A reasonable starting point is 2–5 nM enzyme in your reaction well when using a fluorogenic substrate such as dansyl-Ala-Arg at 200 µM. Under these conditions, a 60-minute room-temperature incubation typically yields a quantifiable signal with a good signal-to-background ratio. If you are screening inhibitors and need a robust assay window, titrate enzyme from 1 to 20 nM and choose the concentration that gives 20–40% substrate conversion in 30 minutes — this keeps the assay in the linear range and reduces substrate depletion artifacts that confound IC₅₀ determinations.

Can I use recombinant Carboxypeptidase Z as a positive control for Western blot with the matched TPB antibody RP-CarboxypeptidaseZ?

Yes — this is one of the primary intended uses. The recombinant (REC-CarboxypeptidaseZ) and the matched rabbit polyclonal antibody (RP-CarboxypeptidaseZ) are developed in the same lab and guaranteed compatible. Loading 10–50 ng of recombinant protein per lane alongside your cell lysate samples gives a clean, reproducible band at ~80–90 kDa under reducing conditions. This positive control is especially useful when validating RP-CarboxypeptidaseZ against a new cell line or tissue lysate, confirming antibody performance independently of endogenous expression levels.

How much recombinant Carboxypeptidase Z should I load for a Western blot positive control lane?

Load 20–50 ng per lane as a starting point; this reliably produces a detectable band with RP-CarboxypeptidaseZ at a primary antibody dilution of 1:1,000–1:5,000. If your film or imager tends toward high background, drop to 10 ng and confirm linearity. Because the HEK293-expressed protein is glycosylated, the band will appear at ~80–90 kDa rather than the sequence-predicted ~73 kDa — account for this when comparing to molecular weight markers so you do not misidentify the band. Run the recombinant under the same reducing conditions as your experimental samples for a fair comparison.

How should I store and handle recombinant Carboxypeptidase Z to maintain activity over time?

The protein is supplied as a ready-to-use solution in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ and should be stored at −20°C in single-use aliquots. Repeated freeze-thaw cycles progressively reduce metallocarboxypeptidase activity by disrupting zinc coordination; aliquot on receipt to avoid this. On the day of use, thaw on ice and briefly centrifuge to pellet any microaggregates. Working stocks diluted in assay buffer can be held on ice for up to 4 hours; do not leave the enzyme at 37°C for extended periods outside an active assay. Purity is >90% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL.

Validation imagery coming soon

Western blot validation figures for REC-CarboxypeptidaseZ will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →